RhumbLine Advisers
ARTV

RhumbLine Advisers’s Artiva Biotherapeutics ARTV Stock Holding History

RhumbLine Advisers’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29.5K Buy
+3,039
New +$27.7K ﹤0.01% 3770
2025
Q2 		– Sell
-14,493
Closed -$43.5K – 4293
2025
Q1 		$43.5K Buy
14,493
+1,614
+13% +$8.71K ﹤0.01% 3606
2024
Q4 		$130K Sell
12,879
-1,950
-13% -$23.4K ﹤0.01% 3394
2024
Q3 		$229K Buy
+14,829
New +$172K ﹤0.01% 3169

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

RhumbLine Advisers's ARTV Position: Q2 2026 in Review

RhumbLine Advisers opened a new position in Artiva Biotherapeutics (ARTV) in Q2 2026: 3,039 shares worth $29.5K. The stake represents ﹤0.01% of the portfolio and ranks #3770 among its holdings. This is a return to the name: RhumbLine Advisers previously reported a position in ARTV as recently as Q1 2025.

RhumbLine Advisers first reported a position in ARTV in Q3 2024 and has held it in 4 quarters since. The position peaked at $229K in Q3 2024. 72 funds tracked by Wall St. Rank hold ARTV as of Q2 2026.

  • RhumbLine Advisers held 3,039 shares of Artiva Biotherapeutics worth $29.5K as of Q2 2026.
  • Artiva Biotherapeutics was a new RhumbLine Advisers position in Q2 2026.
  • Artiva Biotherapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3770 holding.
  • RhumbLine Advisers first reported a position in Artiva Biotherapeutics in Q3 2024 and has held it in 4 quarters since.
  • RhumbLine Advisers's Artiva Biotherapeutics position peaked at $229K in Q3 2024.
  • 72 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.